Anti-Viral Therapy in Alzheimer's Disease
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Alzheimer's Disease
-
Age: Between 55 Year(s) - 95 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Subjects must be between the age fo 15 to 95 years old
- Female subjects must be postmenopausal defined as 12 consecutive months without menstruation.
- Subjects who have diagnosis of probable AD by NIA clinical diagnostic criteria.
- Subjects must score 18 to 28 out of 30 on the Folstein Mini State
- Subjects must score clinical Dementia Rating (CDR) score of 1
- Subjects must have a family member or other individual who is in contact with the patient and consents to serve as informant during the study
- Subjects retains capacity to consent for him/herself or retains the capacity to identify a surrogate who will consent on his/her behalf.
- Subjects must test positive for serum antibodies to HSV1 or HSV2.
- Subjects have use of cholinesterase inhibitors and memantine, and concomitant psychotropic medications
You may not be eligible for this study if the following are true:
-
- Subjects' caregiver is unwilling or unable, in the opinion of the investigator, to comply with study instructions.
- Subjects who have dementia predominantly of non-Alzheimer's type, including vascular dementia, frontotemporal dementia, Lewy body dementia, substance-induced dementia.
- Subjects must score greater than 4 on the Modified Hachinski scale
- Subjects with Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis, bipolar disorder or current major depression by DSM-5 criteria.
- Subjects with active suicidal intent or plan based on clinical assessment.
- Subjects who have current or recent (past 6 months) alcohol or substance use disorder
- Subjects with history of alcohol or drug abuse within 12 months prior to the date informed consent is obtained
- Subjects who have current diagnosis of other major neurological disorders, including Parkinson's disease, multiple sclerosis, CNS infection, Huntington' s disease, and amyotrophic lateral sclerosis
- Subjects with sitting blood pressure > 160/100 mm Hg
- Subjects with renal failure
- Subjects have serum vitamin B12 levels below the normal range.
- Subjects with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
- Use of benzodiapezines in lorazepam equivalent doses equal to or greater than 2 mg daily.
- Subjects consenting to lumbar puncture (40% of sample), this procedure will be conducted if there is no lower spinal malformation or other contraindication to lumbar puncture
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.